Alzheimer’s Disease | Disease Landscape and Forecast | G7 | 2021
The Alzheimer’s disease (AD) market comprises a handful of symptomatic treatment options that offer modest efficacy for a limited duration, leaving clear opportunity for more-effective alternatives—in particular, disease-modifying therapies (DMTs), which are numerous and span a range of mechanisms, drug targets (e.g., beta amyloid, tau), and clinical profiles. Considerable doubt remains about the clinical prospects of DMTs targeting the amyloid cascade (e.g., from Biogen, Eisai, Roche, and Eli Lilly), and interviewed experts are cautiously optimistic about the many anti-tau therapies entering mid-phase trials. Meanwhile, hope remains for late-phase therapies from Lundbeck, Otsuka, Avanir, and Axsome that are in development for the treatment of agitation. Ultimately, the launch of these potential blockbusters is far from certain but could return a heavily generic market to enormous growth.
QUESTIONS ANSWERED
- How large is the treatable AD population? What will be the impact of DMTs (should any launch) on diagnosis / drug treatment rates?
- What are the KOLs’ opinions of Biogen’s aducanumab and other agents in development (e.g., lecanemab, donanemab, gantenerumab)?
- What commercial uptake can be expected from Rexulti, AVP-786,and AXS-05 should they launch for AD agitation?
- What are the drivers and constraints in the AD market, and how might they change over the forecast period as premium-priced agents enter the market?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
